Total Payments
$296,886
2024 Payments
$145.91
Companies
34
Transactions
366
Medicare Patients
8,331
Medicare Billing
$791,112
Payment Breakdown by Category
Research$285,370 (96.1%)
Food & Beverage$5,749 (1.9%)
Travel$5,608 (1.9%)
Education$158.76 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $285,370 | 58 | 96.1% |
| Food and Beverage | $5,749 | 284 | 1.9% |
| Travel and Lodging | $5,608 | 20 | 1.9% |
| Education | $158.76 | 4 | 0.1% |
Payments by Type
Research
$285,370
58 transactions
General
$11,516
308 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Glenmark Pharmaceuticals Inc. | $204,122 | 20 | $0 (2019) |
| Lupin Inc. | $77,297 | 14 | $0 (2018) |
| GlaxoSmithKline, LLC. | $3,834 | 101 | $0 (2021) |
| AstraZeneca UK Limited | $3,174 | 17 | $0 (2019) |
| Theravance Biopharma Inc. | $1,427 | 5 | $0 (2017) |
| SANOFI US SERVICES INC. | $1,208 | 9 | $0 (2019) |
| Shionogi Inc | $1,172 | 13 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $1,064 | 8 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $491.29 | 30 | $0 (2024) |
| Genentech USA, Inc. | $437.71 | 26 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $145.91 | 5 | Regeneron Healthcare Solutions, Inc. ($79.94) |
| 2023 | $182.71 | 9 | United Therapeutics Corporation ($85.54) |
| 2022 | $83.79 | 4 | Insmed, Inc. ($40.50) |
| 2021 | $122.36 | 9 | GlaxoSmithKline, LLC. ($48.62) |
| 2020 | $3,314 | 59 | GlaxoSmithKline, LLC. ($1,650) |
| 2019 | $5,835 | 112 | Glenmark Pharmaceuticals Inc. ($2,001) |
| 2018 | $88,669 | 84 | Lupin Inc. ($77,297) |
| 2017 | $198,533 | 84 | Glenmark Pharmaceuticals Inc. ($192,824) |
All Payment Transactions
366 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: Respiratory | ||||||
| 10/31/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: Respiratory | ||||||
| 08/07/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $18.22 | General |
| Category: Respiratory | ||||||
| 07/22/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Education | In-kind items and services | $79.94 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 03/06/2024 | Resmed Corp | AIRSENSE (Device) | Education | Cash or cash equivalent | $14.20 | General |
| Category: Sleep | ||||||
| 12/12/2023 | Philips Electronics North America Corporation | (8874) inCourage (Device) | Food and Beverage | Cash or cash equivalent | $14.60 | General |
| Category: Medical Device | ||||||
| 11/30/2023 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $26.81 | General |
| Category: PAH | ||||||
| 11/01/2023 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $27.97 | General |
| Category: PAH | ||||||
| 10/26/2023 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $30.76 | General |
| Category: PAH | ||||||
| 08/01/2023 | Philips Electronics North America Corporation | (8874) inCourage (Device) | Food and Beverage | Cash or cash equivalent | $19.00 | General |
| Category: Medical Device | ||||||
| 07/26/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $13.83 | General |
| Category: Respiratory | ||||||
| 06/26/2023 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $14.88 | General |
| Category: Pulmonology | ||||||
| 06/20/2023 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $22.01 | General |
| Category: Pulmonology | ||||||
| 04/18/2023 | Philips Electronics North America Corporation | (8874) inCourage (Device) | Food and Beverage | Cash or cash equivalent | $12.85 | General |
| Category: Medical Device | ||||||
| 09/08/2022 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: Respiratory | ||||||
| 08/09/2022 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: Respiratory | ||||||
| 04/11/2022 | Olympus America Inc. | ENDOCAPSULE SOFTWARE 10 (Device) | Food and Beverage | In-kind items and services | $16.34 | General |
| Category: Medical Solutions Division | ||||||
| 03/04/2022 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $26.95 | General |
| Category: NEUROLOGY | ||||||
| 12/02/2021 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $14.69 | General |
| 10/29/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $12.61 | General |
| Category: RESPIRATORY | ||||||
| 08/25/2021 | Janssen Scientific Affairs, LLC | Cabenuva (Drug) | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: Infectious Diseases | ||||||
| 07/20/2021 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $14.94 | General |
| Category: Pulmonology | ||||||
| 05/10/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $11.46 | General |
| Category: RESPIRATORY | ||||||
| 03/08/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $13.22 | General |
| Category: RESPIRATORY | ||||||
| 02/22/2021 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $11.50 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GSP304-201 | Glenmark Pharmaceuticals Inc. | $192,824 | 16 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $74,297 | 13 |
| Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Glenmark Pharmaceuticals Inc. | $9,298 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ADMINISTRATION OF FLUTICASONE PROPIONATE 100 MCG AND SALMETEROL XINAFOATE 50 MCG DRY POWDER INHALER COMPARED TO ADMINISTRATION WITH ADVAIR DISKUS 10050 MCG TWICE DAILY AND PLACEBO IN PATIENTS 12 YEARS OF AGE AND OLDER WITH REVERSIBLE PERSISTENT ASTHMA INCLUDING A 3-WEEK OPEN-LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $3,000 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD) | Glenmark Pharmaceuticals Inc. | $2,001 | 2 |
| A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | GlaxoSmithKline, LLC. | $1,461 | 11 |
| A 24 month double blind randomised parallel group study to determine the effect of Anoro on symptoms vs Tiotropium | GlaxoSmithKline, LLC. | $1,282 | 4 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi | SANOFI US SERVICES INC. | $1,208 | 9 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 2,206 | 3,167 | $413,045 | $194,744 |
| 2022 | 17 | 1,885 | 2,874 | $366,484 | $167,813 |
| 2021 | 17 | 2,049 | 3,100 | $403,225 | $197,438 |
| 2020 | 19 | 2,191 | 3,698 | $507,936 | $231,117 |
Total Patients
8,331
Total Services
12,839
Medicare Billing
$791,112
Procedure Codes
77
All Medicare Procedures & Services
77 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 362 | 558 | $81,660 | $50,546 | 61.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 166 | 755 | $113,250 | $45,005 | 39.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 370 | 432 | $43,560 | $26,529 | 60.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 145 | 162 | $38,880 | $20,443 | 52.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 158 | 158 | $31,550 | $19,616 | 62.2% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 454 | 533 | $45,305 | $10,114 | 22.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 29 | 32 | $5,875 | $4,393 | 74.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 76 | 78 | $5,965 | $2,889 | 48.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 31 | 31 | $4,715 | $2,565 | 54.4% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 88 | 88 | $11,440 | $2,498 | 21.8% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 52 | 52 | $5,200 | $2,049 | 39.4% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 52 | 52 | $5,200 | $2,022 | 38.9% |
| 95012 | Test to measure the level of nitric oxide gas | Office | 2023 | 111 | 116 | $5,800 | $1,553 | 26.8% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 55 | 60 | $4,920 | $1,509 | 30.7% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2023 | 19 | 19 | $3,800 | $1,325 | 34.9% |
| 31623 | Exam of lung airways using an endoscope | Facility | 2023 | 11 | 12 | $3,960 | $958.28 | 24.2% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 11 | 12 | $690.00 | $468.16 | 67.8% |
| 94762 | Test to measure oxygen level in blood using ear or finger device continuously overnight | Office | 2023 | 16 | 17 | $1,275 | $262.08 | 20.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 395 | 693 | $97,020 | $58,870 | 60.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 139 | 681 | $102,150 | $35,230 | 34.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 328 | 377 | $35,815 | $21,733 | 60.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 128 | 144 | $34,560 | $19,895 | 57.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 89 | 89 | $15,575 | $10,034 | 64.4% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 422 | 494 | $41,990 | $8,949 | 21.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 58 | 58 | $4,350 | $2,091 | 48.1% |
About Dr. Michael Denenberg, M.D
Dr. Michael Denenberg, M.D is a Sleep Medicine healthcare provider based in Rock Hill, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538173794.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Denenberg, M.D has received a total of $296,886 in payments from pharmaceutical and medical device companies, with $145.91 received in 2024. These payments were reported across 366 transactions from 34 companies. The most common payment nature is "" ($285,370).
As a Medicare-enrolled provider, Denenberg has provided services to 8,331 Medicare beneficiaries, totaling 12,839 services with total Medicare billing of $791,112. Data is available for 4 years (2020–2023), covering 77 distinct procedure/service records.
Ad
Practice Information
- Specialty Sleep Medicine
- Other Specialties Pulmonary Disease
- Location Rock Hill, SC
- Active Since 07/27/2006
- Last Updated 04/27/2018
- Taxonomy Code 207RS0012X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1538173794
Products in Payments
- TIOTROPIUM (Drug) $74,297
- ADVAIR (Drug) $3,000
- NUCALA (Biological) $1,653
- ANORO (Drug) $1,576
- DUPIXENT (Drug) $1,490
- FASENRA (Drug) $1,149
- MK-7264 (Drug) $1,034
- TRELEGY ELLIPTA (Drug) $413.99
- Prolastin-C Liquid (Biological) $340.42
- Arikayce (Drug) $313.56
- SYMBICORT (Drug) $290.75
- Xolair (Biological) $238.36
- Esbriet (Biological) $199.35
- OFEV (Drug) $164.91
- STIOLTO RESPIMAT (Drug) $141.55
- Xyrem (Drug) $133.91
- BREO (Drug) $132.31
- OPSUMIT MACITENTAN (Drug) $124.54
- DUPIXENT (Biological) $123.05
- ACTHAR (Biological) $120.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.